2025 Speakers

 

Mackenzie Abramson, MPH, BCPA, Patient Advocate & Sr. Manager, Community Engagement and Communications, Global Genes

Dean Aguiar, Vice President, Translational Research, TSC Alliance

Lynn Albizo, Chief Public Policy Officer, Immune Deficiency Foundation

Kathryn Alexander, Consultant, SMS Mom & Advocate

Amanda Almany, Parent Advisor, NKH Crusaders

Ahmad Alrawi, SVP Corporate Strategy, Commense Bio

Kristin Archibald, Founder, NKH Crusaders

Barbara Arone, VP, Global Category Lead​, Evidence Generation for Medical Affairs, IQVIA

Ethan Ash, Senior VP of Business Development, Bionews

Alithea Athans, Patient Columnist, CAD

Leone Atkinson, Executive Medical Director, Rare Disease, Advanced Therapies and Pediatrics Team, Fortrea

Leone Atkinson | Executive Medical Director, Rare Disease, Advanced Therapies and Pediatrics Team | Fortrea » speaking at Orphan Drug Congress

Lisa Bair, Managing Director, Market Access and Payer Marketing, BGB Group

Annette Bakker, CEO, Childrens Tumor Foundation

Ella Balasa, Patient Engagement Consultant, Patient Advocate

Matt Baniak, Vice President of Client and Delivery Excellence, EVERSANA

Tanya Bardakjian, Director, Medical Affairs Diagnostics, Sarepta Therapeutics

Tanya Bardakjian | Director, Medical Affairs Diagnostics | Sarepta Therapeutics » speaking at Orphan Drug Congress

Oliver Barnes, US Pharmaceutical & Biotech Correspondent, Financial Times

Oliver Barnes | US Pharmaceutical & Biotech Correspondent | Financial Times » speaking at Orphan Drug Congress

Erica Barnes, Rare Disease Advisory Council Executive Director, University of Minnesota

Erica Barnes | Rare Disease Advisory Council Executive Director | University of Minnesota » speaking at Orphan Drug Congress

Caitlyn Barrett, Director, Rare Disease and Oncology, Milken Institute Strategic Philanthropy Accelerator for Research and Collaboration (SPARC)

Ron Bartek, President, Co-Founder, Friedreich's Ataxia Research Alliance

Ron Bartek | President, Co-Founder | Friedreich's Ataxia Research Alliance » speaking at Orphan Drug Congress

Thomas Bartlett, Rare Disease Patient Digital Technology Advisor, Bartlett Rare Disease Advocacy

Thomas Bartlett | Rare Disease Patient Digital Technology Advisor | Bartlett Rare Disease Advocacy » speaking at Orphan Drug Congress

Kevin Baruzzi, Partner, Simon-Kucher & Partners Strategy & Marketing Consultants GmbH

Kevin Baruzzi | Partner | Simon-Kucher & Partners Strategy & Marketing Consultants GmbH » speaking at Orphan Drug Congress

Alison Bateman-House, Assistant Professor, Division of Medical Ethics, NYU Grossman School of Medicine

Alison Bateman-House | Assistant Professor, Division of Medical Ethics | NYU Grossman School of Medicine » speaking at Orphan Drug Congress

Andree Bates, Chief Executive Officer, Eularis Ltd

Andree Bates | Chief Executive Officer | Eularis Ltd » speaking at Orphan Drug Congress

Scott Baver, VP, Head of US Medical Affairs, ITF Therapeutics

Scott Baver | VP, Head of US Medical Affairs | ITF Therapeutics » speaking at Orphan Drug Congress

Anne Bechet, Global Head of Clinical Development and General Manager, Europe & USA, JCR Pharma

Natalie M. Beck, MGC, CGC, Senior Manager, Clinical Trials and RWD, Genome Medical

Anny Bedard, President, Egetis Therapeutics US

Anny Bedard | President | Egetis Therapeutics US » speaking at Orphan Drug Congress

Hourinaz Behesti, Founder & CEO, Hebbian Bio

Hourinaz Behesti | Founder & CEO | Hebbian Bio » speaking at Orphan Drug Congress

Allyson Berent, Chief Science Officer, Foundation for Angelman Syndrome Therapeutics, Foundation for Angelman Syndrome Therapeutics

Lara Bloom, President and CEO, The Ehlers-Danlos Society

Adam Bloomfield, M.D., FAAP, Vice President, Medical Affairs, Rare Diseases and Pediatrics, Premier Research

Michelle Boisvert, PhD Student, Harvard Medical School

Michelle Boisvert | PhD Student | Harvard Medical School » speaking at Orphan Drug Congress

Julieta B Bonvin Sallago, Lead Clinical Research Associate/ Assistant Professor, Connecticut Children's/ University of Connecticut School of medicine

Ian Bonzani, Sr. Principal, Real World Technology Solutions, IQVIA

Rohit Borker, Senior Vice President, Value Access, Health Economics & Outcomes Research, RTI Health Solutions

Rohit Borker | Senior Vice President, Value Access, Health Economics & Outcomes Research | RTI Health Solutions » speaking at Orphan Drug Congress

Lesa Brackbill, Associate Director of Advocacy, Patient Advocacy Strategies

Teresa Brandt, VP, Regulatory Affairs, Avidity Biosciences

Christine Brennan, Managing Director, Vertex Ventures HC

Christine Brennan | Managing Director | Vertex Ventures HC » speaking at Orphan Drug Congress

Jonathan Bruce, Vice President, Market Access, Distribution, HEOR, F2G, Inc.

Mariana Burin, Medical Director, Thermo Fisher Scientific

Mariana Burin | Medical Director | Thermo Fisher Scientific » speaking at Orphan Drug Congress

Raquel Cabo, Former SVP Corporate Affairs and Commercial strategy, Ovid Therapeutics

Raquel Cabo | Former SVP Corporate Affairs and Commercial strategy | Ovid Therapeutics » speaking at Orphan Drug Congress

Melody Calkins, Director, Healthcare Policy, Biotechnology Innovation Organization

Mary Callanan, Senior Director, Global Medical Affairs, Alnylam Pharmaceuticals

Mary Callanan | Senior Director, Global Medical Affairs | Alnylam Pharmaceuticals » speaking at Orphan Drug Congress

Mindy Cameron, President, AdvocacyWorks Consulting

Mindy Cameron | President | AdvocacyWorks Consulting » speaking at Orphan Drug Congress

Tanisha Carino, Visiting Fellow, Duke-Margolis Institute for Health Policy

Tanisha Carino | Visiting Fellow | Duke-Margolis Institute for Health Policy » speaking at Orphan Drug Congress

Janet Carlson, CEO, 1.11 Group

Joel Cartner, Director, Access Policy, Muscular Dystrophy Association

Michelle Carty, Senior Principal, Patient Centered Solutions, IQVIA

Cynthia Cassandro, Vice President, Patient Advoacy, Vigil Neuroscience

Cynthia Cassandro | Vice President, Patient Advoacy | Vigil Neuroscience » speaking at Orphan Drug Congress

Jill Castle, Director of Patient Education & Patient Advocacy, Little Hercules Foundation

Grant Castor, SVP Commercial Strategy & Operations, Sentynl Therapeutics

Grant Castor | SVP Commercial Strategy & Operations | Sentynl Therapeutics » speaking at Orphan Drug Congress

Chelsea Catsburg, Director, BluePrint Orphan

Chelsea Catsburg | Director | BluePrint Orphan » speaking at Orphan Drug Congress

James Chambers, Professor, Tufts Medical Center

Hayley Chapman, Senior Program Director, Patient Focused Drug Development

Timothy Chen, Medical Director, Caliway Biopharmaceuticals

Ellen Cho, Senior Director, Specialty Programs, Direct Relief

Ellen Cho | Senior Director, Specialty Programs | Direct Relief » speaking at Orphan Drug Congress

Duane Clark, General Manager, US Rare Disease, Sanofi

Jim Coccia, Partner, TKG Access

Jason Colquitt, Chief Executive Officer, Across Healthcare

Amy Comstock Rick, Director of Strategic Coalitions, Rare Disease Innovation Hub, FDA

Amy Comstock Rick | Director of Strategic Coalitions, Rare Disease Innovation Hub | FDA » speaking at Orphan Drug Congress

Rena Conti, Associate Professor, Markets, Public Policy, and Law, Boston University

Rena Conti | Associate Professor, Markets, Public Policy, and Law | Boston University » speaking at Orphan Drug Congress

Donna Cowan, Director EAP, Stealth BioTherapeutics

Donna Cowan | Director EAP | Stealth BioTherapeutics » speaking at Orphan Drug Congress

Michael Cristello, Director, Marketing, Rare Disease, Sumitomo Pharma

Michael Cristello | Director, Marketing, Rare Disease | Sumitomo Pharma » speaking at Orphan Drug Congress

Eric Crombez, MD, EVP, Chief Medical Officer, Ultragenyx

Eric Crombez, MD | EVP, Chief Medical Officer | Ultragenyx » speaking at Orphan Drug Congress

Glenna Crooks, PhD, Founder and CEO, Strategic Health Policy International, Inc

Lucy Culp, Vice President, State Government Affairs, The Leukemia & Lymphoma Society (LLS)

Andrew Cummins, VP Access and Reimbursement, Sciensus

Andrew Cummins | VP Access and Reimbursement | Sciensus » speaking at Orphan Drug Congress

Colleen Dansereau, RN, Vice President - Emerging Discoveries, Boston Children's Hospital

Marcella Debidda, President Patient Insights & Clinical Solutions, BioNews Clinical

Marcella Debidda | President Patient Insights & Clinical Solutions | BioNews Clinical » speaking at Orphan Drug Congress

Brigid DeCoursey Bondoc, Partner, Morrison Foerster

Daniel DeFabio, Global Genes Director of Education & Co-Founder,, Disorder: The Rare Disease Film Festival

Marcus Delatte, VP, Regulatory Strategy, Allucent

Rumi Desai, Director, Global Regulatory Strategy, Amgen, Inc.

Rumi Desai | Director, Global Regulatory Strategy | Amgen, Inc. » speaking at Orphan Drug Congress

Veruska di Sena, SVP, Head of US Medical Affairs, Intercept Pharmaceuticals, Inc.

Veruska di Sena | SVP, Head of US Medical Affairs | Intercept Pharmaceuticals, Inc. » speaking at Orphan Drug Congress

Bradley Dickerson, VP of Project Management & Patient Advocacy, IECURE Inc

Elizabeth Donahue, Senior Director, Project Management, Thermo Fisher Scientific

Danielle Dong, Global Medical Scientific Advocacy Lead, Rare Disease, Sanofi

Danielle Dong | Global Medical Scientific Advocacy Lead, Rare Disease | Sanofi » speaking at Orphan Drug Congress

Sika Dunyoh, Senior Director of Patient Advocacy, Travere Therapeutics

Heidi Edwards, President & Founder, Sisters’ Hope Foundation

Erika Edwards, Health and Medical Reporter and Writer, NBC News

Erika Edwards | Health and Medical Reporter and Writer | NBC News » speaking at Orphan Drug Congress

Michael Eging, Executive Director, Rare Access Action Project

Jill Elliott, Vice President, Marketing, X4 Pharmaceuticals

Jill Elliott | Vice President, Marketing | X4 Pharmaceuticals » speaking at Orphan Drug Congress

Wendy Erler, Senior Vice President, Patient Affairs, Sarepta Therapeutics

Eric Feigen, Regulatory Affairs Manager, Immune Deficiency Foundation

Anthony Fiori, Senior Managing Director, Manatt

Alicia Fiscus, Head of Global Regulatory Affairs and QA, Rhythm Pharmaceuticals

Alicia Fiscus | Head of Global Regulatory Affairs and QA | Rhythm Pharmaceuticals » speaking at Orphan Drug Congress

Amber Fisher, Senior Clinical Research Manager, Kura Oncology Inc

Amber Fisher | Senior Clinical Research Manager | Kura Oncology Inc » speaking at Orphan Drug Congress

E'Lissa Flores, Director, Science & Regulatory Affairs, Biotechnology Innovation Organization

E'Lissa Flores | Director, Science & Regulatory Affairs | Biotechnology Innovation Organization » speaking at Orphan Drug Congress

Amanda Forys, Managing Partner, Magnolia Market Access

Pangkong Fox, Science Engagement Director, CACNA1A Foundation, Inc.

Pangkong Fox | Science Engagement Director | CACNA1A Foundation, Inc. » speaking at Orphan Drug Congress

Sheila Frame, President and Head of US Business, Gamida Cell Ltd

Karen Frascello, Senior Director, Medical Affairs, Alnylam Pharmaceuticals

Albert Freedman, Counseling Psychologist / Rare Dad, Rarecounseling.com

Robert Fremeau, Founder and CEO, BrainStorm Therapeutics, Inc.

Stacey Frisk, Executive Director, Rare Disease Company Coalition

Stacey Frisk | Executive Director | Rare Disease Company Coalition » speaking at Orphan Drug Congress

Suzanne Gaglianone, Patient Care Field Representative, ReveraGen BioPharma Inc

Suzanne Gaglianone | Patient Care Field Representative | ReveraGen BioPharma Inc » speaking at Orphan Drug Congress

Chris Garabedian, Portfolio Manager, Venture, Perceptive Advisors

Diego Garzon, VP, Corporate Development, Apertura Gene Therapy

Pamela Gavin, Chief Executive Officer, National Organization for Rare Disorders (NORD)

Pamela Gavin | Chief Executive Officer | National Organization for Rare Disorders (NORD) » speaking at Orphan Drug Congress

Victoria Gemme, Director of Policy and Regulatory Affairs, National Organization for Rare Disorders (NORD)

Stephen George, PharmD, MS, SVP Market Access Reimbursment, Milliman

Nayan Ghosh, Head of Life Sciences & HealthTech, Marwood Group

Nayan Ghosh | Head of Life Sciences & HealthTech | Marwood Group » speaking at Orphan Drug Congress

Diego Fernando Gil Cardozo, President, Enfermedades Raras en el Caribe y América Latina (ERCAL)

Anna Gilmore, Senior Director, Education & Advocacy, FSHD Society

Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine

Sonia Gobeil, Cofounder, Ataxia of Charlevoix-Saguenay Foundation

Josie Godfrey, Director, JG Zebra Consulting

Josie Godfrey | Director | JG Zebra Consulting » speaking at Orphan Drug Congress

Federico Goodsaid, SVP Regulatory and Quality, Ariana Pharma

Vivek Gowda, Head of Research, Neoclease

Vivek Gowda | Head of Research | Neoclease » speaking at Orphan Drug Congress

J. Michael Graglia, Co-Founder & Managing Director, Syngap Research Fund

J. Michael Graglia | Co-Founder & Managing Director | Syngap Research Fund » speaking at Orphan Drug Congress

James Griffin, Sickle Cell Patient Advocate, Independent Milwaukee Wisconsin

Kurt Gunter, Clinical Development Advisor, Steminent Biotherapeutics Inc.

David Gusick, Executive Director, Somebody To Talk To

Joern-Peter Halle, Advisor and Venture Partner, BioGeneration Ventures (BGV)

Sonit Handa, Member, Board of Directors, The Josselyn Center

Kate Hanman, US Head of Rare Diseases, Costello Medical

Kate Hanman | US Head of Rare Diseases | Costello Medical » speaking at Orphan Drug Congress

Rachel Harrison, Director, Expanded Access Program, Argenx

Rachel Harrison | Director, Expanded Access Program | Argenx » speaking at Orphan Drug Congress

Thomas Hart, Director of Outreach, Critical Path Institute

Thomas Hart | Director of Outreach | Critical Path Institute » speaking at Orphan Drug Congress

Christina Hartman, Senior Director, Government Affairs, Orchard Therapeutics

Scott Harwood, Director, Check Rare

Scott Harwood | Director | Check Rare » speaking at Orphan Drug Congress

Atalah Haun, MD, Vice President, Medical Affairs, WEP Clinical

Atalah Haun, MD | Vice President, Medical Affairs | WEP Clinical » speaking at Orphan Drug Congress

Guadalupe Hayes Mota, CEO & Co-founder, Stealth Star-up & Senior Lecturer, Massachusetts Institute of Technology

Matthew Hayes, FSA, MAAA, Principal and Consulting Actuary, Milliman

Matthew Hayes, FSA, MAAA | Principal and Consulting Actuary | Milliman » speaking at Orphan Drug Congress

Shane Hegarty, Chief Scientific Officer & Co-Founder, AXONIS Therapeutics

Brandon Michael Henry, Medical Director, Cell and Gene Therapy, IQVIA

Michele Herndon, Program Director, UDNF

Anne Heyes, Vice President, Head of Value Strategy, RTI Health Solutions

Lauren Holder, Producer/Host, Help 4 HD Live Podcast, Help 4 HD

Lauren Holder | Producer/Host, Help 4 HD Live Podcast | Help 4 HD » speaking at Orphan Drug Congress

Elise Hoover, Vice President of Research, Foundation for Sarcoidosis Research

Patrick Hopkinson, Managing Director, 'International HTA Expert

Wills Hughes-Wilson, Chief Patient Access & Commercial Planning, Mereo Biopharma

Raymond Huml, Vice President, Rare & Orphan Strategy, Sciensus

Tim Hunt, Chief Executive Officer, Alliance for Regenerative Medicine

Gwen Hyland, Head of Commercial Excellence, Rare Diseases, AstraZeneca, Alexion Pharmaceuticals

Gwen Hyland | Head of Commercial Excellence, Rare Diseases, AstraZeneca | Alexion Pharmaceuticals » speaking at Orphan Drug Congress

Mohammad Imran, Global BD Head, 3H Medi Solution Inc

Neil Inhaber, Head, Rare Diseases, Global Medical Affairs, Takeda

Debra Jennings, Head of Patient Services Operations, North America, Kyowa Kirin

Gemma Jennings, Global Vice President of Programme Partnerships, BBC STORYWORKS

Zhou Jiang, VP of Early Commercial and Corporate Strategy, Edgewise Therapeutics

Puja Joshi, Medical Director, Clinical Development, Stoke Therapeutics

Richie Kahn, Co-Founder & COO, Canary Advisors

Emil Kakkis, Chief Executive Officer, Ultragenyx Pharmaceutical

Litsa Kapsalis, PhD student, Massachusetts Institute of Technology

Tina Karunaratne, Founder and CEO, Karuna Integrated Clinical Services

Tina Karunaratne | Founder and CEO | Karuna Integrated Clinical Services » speaking at Orphan Drug Congress

Mwango Kashoki, MD, MPH, SVP, Global Head of Regulatory Strategy, Parexel

Joe Katakowski, Director of Research, RTW Foundation

Mandeep Kaur, MD, MS, Board Member, Former SVP Horizon / Amgen

Mandeep Kaur, MD, MS | Board Member | Former SVP Horizon / Amgen » speaking at Orphan Drug Congress

Louise Kearney, Executive Director, Rare disease, Advanced therapies and Pediatrics Team (RAPT), Fortrea

Tara Keith, Freelance writer, Rare disease advisor and SM companion

Tara Keith | Freelance writer | Rare disease advisor and SM companion » speaking at Orphan Drug Congress

Jessica Klein, Patient Advocacy & Industry Relations, Senior Liaison – East Region, Acadia Pharmaceuticals Inc.

Jessica Klein | Patient Advocacy & Industry Relations, Senior Liaison – East Region | Acadia Pharmaceuticals Inc. » speaking at Orphan Drug Congress

Lauren Kopsick, Founder & Executive Director, The Healthcare Navigation Project

Jonathan Kornstein, VP, Rare Disease & Pediatrics Clinical Development, Caidya

Jonathan Kornstein | VP,  Rare Disease & Pediatrics Clinical Development | Caidya » speaking at Orphan Drug Congress

Graeme Ladds, CEO & Owner, PharSafer

Graeme Ladds | CEO & Owner | PharSafer » speaking at Orphan Drug Congress

Lukas Lange, Chief Executive Officer & Co-Founder, Probably Genetic

Patroski Lawson, Co-founder, The Just Society

Kimberly LeBlanc, Director, UDN Data Management Coordinating Center, Harvard Medical School, Harvard Medical School

Connie Lee, Chief Executive Officer, Alliance to Cure Cavernous Malformations

Melanie Lendnal, Senior Vice President, Policy & Advocacy, The ALS Association

Jason Lettiere, Senior Vice President, Corporate and Business Development, Neurvati Neurosciences

Freda C Lewis-Hall, Former Chief Patient Officer And Executive Vice President, Pfizer

Freda C Lewis-Hall | Former Chief Patient Officer And Executive Vice President | Pfizer » speaking at Orphan Drug Congress

Michael Lingzhi Li, Assistant Professor of Business Administration, Harvard Business School, Technology and Operations Management

Dan Lier, Advocate/Patient/Speaker, Somebody To Talk To

Dan Lier | Advocate/Patient/Speaker | Somebody To Talk To » speaking at Orphan Drug Congress

Naomi Litchfield, Director Patient Advocacy, Bionical Emas

Andrew Lo, Charles E. and Susan T. Harris Professor, MIT Sloan School of Management

Andrew Lo | Charles E. and Susan T. Harris Professor | MIT Sloan School of Management » speaking at Orphan Drug Congress

Mathieu Loiseau, Director of Rare Clinical Services, Sciensus

Mathieu Loiseau | Director of Rare Clinical Services | Sciensus » speaking at Orphan Drug Congress

Rob Long, Executive Director, Uplifting Athletes

Veronica Lopez Gousset, MPH, Steering Committee Member, HTAi Rare Disease Interest Group

Peng Lu, Chief Medical Officer, Pharvaris

Vera Luxner, Director of Advocacy Relations, Rare Disease Advisor

Larry Luxner, -, -

Larry Luxner | - | - » speaking at Orphan Drug Congress

Alastair MacDonald, Vice President, Medical Affairs, Sciensus

Kim MacDonnell, Associate Director, Rare Disease, Parexel

Kim MacDonnell | Associate Director, Rare Disease | Parexel » speaking at Orphan Drug Congress

Victor Maertens, Government Affairs Director, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Victor Maertens | Government Affairs Director | European Confederation of Pharmaceutical Entrepreneurs (Belgium) » speaking at Orphan Drug Congress

Alexandra Mangili, Clinical Science Head, Alfasigma

Alexandra Mangili | Clinical Science Head | Alfasigma » speaking at Orphan Drug Congress

Maureen Mansfield, Vice-Chair, ENET and Founder, Protect Your Passion

Maureen Mansfield | Vice-Chair, ENET and Founder | Protect Your Passion » speaking at Orphan Drug Congress

Yuri Maricich, MD, MBA;, Chief Medical Officer, CAMP4 Therapeutics

Silas Martin, Head, Access & Policy Research, Johnson & Johnson

Craig Martin, Founder, CEO, Orphan Therapeutics Accelerator

Craig Martin | Founder, CEO | Orphan Therapeutics Accelerator » speaking at Orphan Drug Congress

Kristin Marvin-Keller, Managing Director, Havas Life Rare

Kristin Marvin-Keller | Managing Director | Havas Life Rare » speaking at Orphan Drug Congress

Fabiana Marzabal, Sr Director Forecasting, Analytics and Insights, Viridian Therapeutics

Cara Mayfield, VP, Corporate Affairs, Neurogene

Maurizio Mazzi, Senior Associate Director, Patient Advocacy & Professional Relations, Böhringer Ingelheim

Reenie McCarthy, Chief Executive Officer, Stealth BioTherapeutics

Katie McCarthy, SVP & Practice Lead, Clinical & Regulatory, Lumanity

Alice McConnell, Chief Executive Officer, Speragen, Inc

Alice McConnell | Chief Executive Officer | Speragen, Inc » speaking at Orphan Drug Congress

Mary McGowan, Chief Executive Officer, Foundation for Sarcoidosis Research

Mary McGowan | Chief Executive Officer | Foundation for Sarcoidosis Research » speaking at Orphan Drug Congress

Jennifer McNary, Co-Founder, Canary Advisors

Jennifer McNary | Co-Founder | Canary Advisors » speaking at Orphan Drug Congress

Juliane Mills, Senior Director, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials

Ana Mingorance, Chief Development Officer, Loulou Foundation

Maryam Mokhtarzadeh, Senior Director Regulatory Strategy, REGENXBIO

Juliet Moritz, Senior VP Strategic Solutions and Patient Centricity, Ergomed

Mary Morlino, Patient Navigator, Undiagnosed Disease Network Foundation (UDNF)

Rachit Mukkamala, President, MIT Biotech Group, Massachusetts Institute of Technology

Joe Musumeci, President, BluePrint Orphan

Joe Musumeci | President | BluePrint Orphan » speaking at Orphan Drug Congress

Ramaiah Muthyala, Professor/Director at University of Minnesota, President and Chief Executive Officer,, Indian organization for Rare diseases

Brian Nappi, SVP, Strategy, Saol Therapeutics

Ramaa Nathan, VP of Data Science and Real-World Evidence, EVERSANA

Amy Nicole Nayar, Vice President of U.S. Patient Advocacy & Government Affairs, Novartis Gene Therapies

Kaylee Nguyen, Senior Conference Director, Terrapinn

Kaylee Nguyen | Senior Conference Director | Terrapinn » speaking at Orphan Drug Congress

Katie Niemeyer, Speaker, Philanthropist, CRNA, SJS Survivor, Katie Niemeyer, Speaker LLC

Kevan Oconnor, Venture Investor, Cystic Fibrosis Foundation

Eunhee Ohgami, CEO, NeuroCores, Inc.

Paula Orandash, Director, Patient Engagement, Ergomed

Michele M Oshman, Chief Patient Advocate & Head, Patient Advocacy Center of Excellence, Biotechnology Innovation Organization

Francis Pang, SVP Global Market Access and International Geographic Expansion, Orchard Therapeutics

Francis Pang | SVP Global Market Access and International Geographic Expansion | Orchard Therapeutics » speaking at Orphan Drug Congress

Alexandre Pare, Scientific Researcher, McGill University

Alexandre Pare | Scientific Researcher | McGill University » speaking at Orphan Drug Congress

Effie Parks, Podcast Host, CTNNB1 Connect & Cure, Once Upon A Gene - CTNNB1

Effie Parks | Podcast Host,  CTNNB1 Connect & Cure | Once Upon A Gene - CTNNB1 » speaking at Orphan Drug Congress

Simrit Parmar, Founder, cellenkos

Kinnari Patel, President, Head of R&D and COO, Rocket Pharma

Doug Paul, VP Commercial Strategy, Cypress Biopharma

Doug Paul | VP Commercial Strategy | Cypress Biopharma » speaking at Orphan Drug Congress

Dave Pearce, Chair, International Rare Diseases Research Consortium (IRDiRC)

Dave Pearce | Chair | International Rare Diseases Research Consortium (IRDiRC) » speaking at Orphan Drug Congress

Allison Peck, Co-Foundet, Cure VCP Disease

Melissa Penn, Director Patient Engagement Research & Development, Bayer

Melissa Penn | Director Patient Engagement Research & Development | Bayer » speaking at Orphan Drug Congress

Mike Porath, Founder, Executive Director, Dup15q Alliance, The Mighty

Mike Porath | Founder, Executive Director, Dup15q Alliance | The Mighty » speaking at Orphan Drug Congress

Bryce Powerman, Director, Business Development, Natera

Bryce Powerman | Director, Business Development | Natera » speaking at Orphan Drug Congress

Matthew Prentice, Director of State Policy, Immune Deficiency Foundation

Matthew Prentice | Director of State Policy | Immune Deficiency Foundation » speaking at Orphan Drug Congress

Raymond Puerini, Director, FasterCures, a Center of the Milken Institute

Donovan Quill, EVP of Life Science Strategies, AscellaHealth

Maha Radhakrishnan, Executive Partner, Sofinnova Investments

Harsha Rajasimha, Founder and Chairman, IndoUSrare

Harsha Rajasimha | Founder and Chairman | IndoUSrare » speaking at Orphan Drug Congress

Patrick Raletz, Project Manager, Bionical Emas

Harpreet Ram, President, EVR Consulting

Dhaval Rathod, Associate Director, Pharm Sci, Shionogi Inc

Dorian Readnour, Vice President, International, Sarepta Therapeutics

Sabrina Rebello, Senior Program Manager, Amyloidosis Research Consortium

Lindsay Reel, VP, Pharmacy Practice & Specialty Solutions, EVERSANA

Rebecca Reimers, Medical Geneticist, Rady Children's Institute for Genomic Medicine

Deborah Requesens, Founder, Society of Hispanic Rare Diseases

Sumira Riaz, Health Psychologist & Patient Engagement Consultant, Unboxed Psychology

Faisal Riaz, Medical Director Neuroimmunology and AATD, Takeda Pharmaceuticals USA Inc

Sara Riordan, Vice President, Strategy, Genome Medical

Sara Riordan | Vice President, Strategy | Genome Medical » speaking at Orphan Drug Congress

Frank Rivera, President, Stronger Than Sarcoidosis

Frank Rivera | President | Stronger Than Sarcoidosis » speaking at Orphan Drug Congress

Luis Rojas, Chief Clinical Development Officer, Polaryx Therapeutics

Luis Rojas | Chief Clinical Development Officer | Polaryx Therapeutics » speaking at Orphan Drug Congress

Hector Rosado, Director, Business Strategy & Operations, Takeda

Hector Rosado | Director, Business Strategy & Operations | Takeda » speaking at Orphan Drug Congress

Luke Rosen, Founder, Rescue 7: Firefighters for Patients

Johanna Rossell, Senior Vice President, General Manager, Sumitomo Pharma

Seth Rotberg, Senior Manager, Patient Advocacy, Solid Biosciences

Jean-Pascal Roussy, Head, Global Public Affairs, Rare Diseases, Sanofi

Christian Rubio, Executive Director, EverythingALS

Christopher Rudolf, Founder and Chief Executive Officer, Volv Global

Pierantonio Russo, FCCP, FAAP, STS, Corporate Chief Medical Officer, EVERSANA

Matt Salo, CEO, Salo Health Strategies

Marina Sardone, Global Head of Patient Advocacy, Alfasigma

William Sarraille, Adjunct Professor, University of Maryland Francis King Carey School of Law

William Sarraille | Adjunct Professor | University of Maryland Francis King Carey School of Law » speaking at Orphan Drug Congress

Mary Schaheen, President, Prevail Partners Llc

Jeremy Schmahmann, Founding Director, Massachusetts General Hospital Ataxia Center, Massachusetts General Hospital Ataxia Center

Jeremy Schmahmann | Founding Director, Massachusetts General Hospital Ataxia Center | Massachusetts General Hospital Ataxia Center » speaking at Orphan Drug Congress

Jörg Schüttrumpf, Chief Scientific Innovation Officer, Grifols

Jörg Schüttrumpf | Chief Scientific Innovation Officer | Grifols » speaking at Orphan Drug Congress

Carolyn Schwartz, President & Chief Scientist, DeltaQuest Foundation

Jessica Scott, Chief Executive Officer, Legacy Health Strategies

Josephine Scrofani, Customer Strategy Lead, Bayer Pharmaceuticals

Josephine Scrofani | Customer Strategy Lead | Bayer Pharmaceuticals » speaking at Orphan Drug Congress

Simone Seiter, Senior Partner, Simon-Kucher & Partners Strategy & Marketing Consultants GmbH

Simone Seiter | Senior Partner | Simon-Kucher & Partners Strategy & Marketing Consultants GmbH » speaking at Orphan Drug Congress

Kathy Senecal, Volunteer, Rare Disease Patient

Kathy Senecal | Volunteer | Rare Disease Patient » speaking at Orphan Drug Congress

Seungoh Seo, Senior AI Researcher, ONCOCROSS

Seungoh Seo | Senior AI Researcher | ONCOCROSS » speaking at Orphan Drug Congress

Bridget Seritt, Founder, Advocates for Compassionate Therapy Now

Bridget Seritt | Founder | Advocates for Compassionate Therapy Now » speaking at Orphan Drug Congress

Andrew Shao, SVP of Global Scientific and Regulatory Affairs, Niagen Bioscience Inc

Jordan Shin, Chief Medical Officer, HAYA Therapeutics

Jordan Shin | Chief Medical Officer | HAYA Therapeutics » speaking at Orphan Drug Congress

Tricha Shivas, Chief Staff and Strategy, Foundation for Sarcoidosis Research

Elan Shuker, Director Of Development, Programme Partnerships, BBC

Jennifer Shumsky, Founder and Principal, JLS Consulting LLC

Jennifer Shumsky | Founder and Principal | JLS Consulting LLC » speaking at Orphan Drug Congress

Jennifer Siedman, Director of Community Engagement, Courageous Parents Network Inc

Amanda Singleton, Medical Affairs Director, Biopharma & Patient Advocacy, GeneDx

Amanda Singleton | Medical Affairs Director, Biopharma & Patient Advocacy | GeneDx » speaking at Orphan Drug Congress

Ted Slocomb, Managing Partner, TS BioAdvisors

Jayson Slotnik, Partner, Health Policy Strategies, LLC

Jayson Slotnik | Partner | Health Policy Strategies, LLC » speaking at Orphan Drug Congress

Stephanie Sloves, Senior Director, Brand Strategy, BGB Group

Rachel Smith, Executive Director, Global Head of Rare Disease, CoE, Parexel

Jennifer Snow, Founder and Principal, Apteka LLC

Frank Sorgi, President and Chief Executive Officer, FLAG Therapeutics

Mangala Soundar, Senior Director, Discovery Neurology,, PepGen

Mangala Soundar | Senior Director, Discovery Neurology, | PepGen » speaking at Orphan Drug Congress

Steve St. Onge, SVP - Corporate Development, Clarametyx Biosciences

Dionne Stalling, Executive Director, Rare And Black

Dionne Stalling | Executive Director | Rare And Black » speaking at Orphan Drug Congress

Stephanie Steele, Director, Immune Deficiency Foundation

Andrew Steinsapir, Acting Chief Technology Officer, Apertura Gene Therapy

Andrew Steinsapir | Acting Chief Technology Officer | Apertura Gene Therapy » speaking at Orphan Drug Congress

Swami Subramanian, Sr. Director, US/Global Pricing, Regeneron Pharmaceuticals Inc

Swami Subramanian | Sr. Director, US/Global Pricing | Regeneron Pharmaceuticals Inc » speaking at Orphan Drug Congress

Hiroshi Sugimoto, Director, Takeda Pharmaceuticals

Erin Sullivan, Executive Director, Sisters’ Hope Foundation

Donna Sullivan, Director of patient advocacy, Pathways to Trust

Marshall Summar, Chief Executive Officer, Uncommon Cures

Fabian Suri-Payer, PhD Candidate, Harvard Medical School

Fabian Suri-Payer | PhD Candidate | Harvard Medical School » speaking at Orphan Drug Congress

Jean Swidler, Executive Director, End the Legacy

Jean Swidler | Executive Director | End the Legacy » speaking at Orphan Drug Congress

Amy Teets, Global Head Patient Strategy, Specialty Care, Sanofi

Amy Teets | Global Head Patient Strategy, Specialty Care | Sanofi » speaking at Orphan Drug Congress

Pierre A Teulié, CEO, ODDIFACT

Betsy Trainor, Board Member, Ataxia of Charlevoix-Saguenay Foundation

Chelsea Trengrove, CEO and Cofounder, Neoclease

Chelsea Trengrove | CEO and Cofounder | Neoclease » speaking at Orphan Drug Congress

Matt Trudeau, President, ITF Therapeutics

Karen Tubridy, Chief Operating Officer, Abcuro, Inc.

Anna Valsamaki, Senior Vice President of Translation Operations,, BIG Language Solutions

Leon van Wouwe, Clinical Innovation Director, Volv Global

Daniel Wainstock, Researcher and Rare Disease Advocate, PUC-Rio

Daniel Wainstock | Researcher and Rare Disease Advocate | PUC-Rio » speaking at Orphan Drug Congress

Jenifer Waldrop, Executive Director, Rare Disease Diversity Coalition, BWHI

Jenifer Waldrop | Executive Director | Rare Disease Diversity Coalition, BWHI » speaking at Orphan Drug Congress

Colin Werth, Pharma Consultant, Patient Advocate

Melissa Williams, CEO, Simply Patient

Susan Winckler, Chief Executive Officer, Reagan Udall Foundation for the F.D.A.

Jodi Wolff, Founder, Strategic Advocacy Solutions, LLC

Jodi Wolff | Founder | Strategic Advocacy Solutions, LLC » speaking at Orphan Drug Congress

Rosangela Wolff Moro, Congresswoman, Federal Chamber of Deputies, São Paulo, Brazil

Rosangela Wolff Moro | Congresswoman | Federal Chamber of Deputies, São Paulo, Brazil » speaking at Orphan Drug Congress

Sorrel Wolowacz, Head European Health Economics, R.T.I. Health Solutions

Durhane Wong-Rieger, President, Chief Executive Officer, Canadian Organisation for Rare Disorder & Rare Diseases International

Susan Woolner, Hauenstein Neurosciences Patient & Caregiver Support/Community Partner Manager, Trinity Health MI

Susan Woolner | Hauenstein Neurosciences Patient & Caregiver Support/Community Partner Manager | Trinity Health MI » speaking at Orphan Drug Congress

Alyssa Wyant, Chief Regulatory & Quality Officer, Praxis Precision Medicines

Alyssa Wyant | Chief Regulatory & Quality Officer | Praxis Precision Medicines » speaking at Orphan Drug Congress

David Young, President, Research & Development and Founder, Processa Pharmaceuticals, Inc.

Joseph Zabinski, VP, Head of Commercial Strategy & AI, OM1

Samantha Zappia, MS, RAC, Regulatory Affairs Consultant, SK Regulatory Solutions

Samantha Zappia, MS, RAC | Regulatory Affairs Consultant | SK Regulatory Solutions » speaking at Orphan Drug Congress

Sophia Zilber, Vice President, Cure Mito Foundation

Jody Zschiedrich, Head of Strategy, Havas Life Rare

Get Involved At World Orphan Drug Congress USA

 

Connect with us

 
 
 
 

 

To Sponsor Or Exhibit

 
 

Justin Franks
justin.franks@terrapinn.com
t/ +1 914 819 3506

 

 

 

To Speak

 
 

Kaylee Nguyen
kaylee.nguyen@terrapinn.com
 

 

 

 

Marketing & Press

 
 

Kaylie Brogan
kaylie.brogan@terrapinn.com